Literature DB >> 15146432

Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis.

Dominique Baeten1, Holger Jon Møller, Joris Delanghe, Eric M Veys, Søren K Moestrup, Filip De Keyser.   

Abstract

OBJECTIVE: Since CD163+ macrophages are selectively increased in spondylarthropathy (SpA) synovitis, we investigated the role of CD163+ macrophages in synovial inflammation.
METHODS: Synovial biopsy samples from 26 SpA and 23 rheumatoid arthritis (RA) patients were analyzed for macrophage and lymphocyte subsets. Synovial fluid (SF) samples were analyzed by Western blotting and enzyme-linked immunosorbent assay for soluble CD163 (sCD163) and by flow cytometry for lymphocyte activation. We also analyzed sCD163 in sera from 100 SpA patients, 23 RA patients, 20 healthy controls, and 20 SpA patients treated with infliximab. Polymorphism of haptoglobin (Hp), the CD163 ligand, was determined in 130 SpA and 23 RA patients.
RESULTS: CD163+ macrophages, but not CD68+ macrophages, were significantly increased in SpA versus RA synovium and in HLA-B27+ versus HLA-B27- SpA. Despite similar lymphocyte numbers, activated lymphocytes (CD69+) were significantly decreased in SpA versus RA patients, with an inverse correlation between CD163 and CD69 levels. Local production of sCD163 was evidenced by a 5-7-fold higher level of sCD163 in SF than in serum and by the correlation with synovial lining CD163+ macrophages in SpA. SF sCD163 levels correlated directly with global inflammation but correlated inversely with CD69+ SF T lymphocytes in the synovium. In contrast, serum sCD163 levels were only moderately increased, did not correlate with SF sCD163 levels or parameters of inflammation, and were unaffected by infliximab therapy. The distribution of Hp polymorphism was not altered in SpA and was not related to CD163 expression.
CONCLUSION: Increased numbers of CD163+ macrophages in SpA synovium and local production of sCD163 are associated with global inflammation as well as impairment of T cell activation, suggesting a dual role for CD163+ macrophages in SpA synovitis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15146432     DOI: 10.1002/art.20174

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  38 in total

1.  Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy.

Authors:  E Kruithof; D Baeten; F Van den Bosch; H Mielants; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2004-09-23       Impact factor: 19.103

Review 2.  Pathogenesis of spondyloarthritis: insights from synovial membrane studies.

Authors:  Leen De Rycke; Elli Kruithof; Bernard Vandooren; Paul P Tak; Dominique Baeten
Journal:  Curr Rheumatol Rep       Date:  2006-08       Impact factor: 4.592

3.  Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical trials in rheumatoid arthritis.

Authors:  D Baeten; J Houbiers; E Kruithof; B Vandooren; F Van den Bosch; A M Boots; E M Veys; A M M Miltenburg; F De Keyser
Journal:  Ann Rheum Dis       Date:  2006-01-13       Impact factor: 19.103

4.  Evidence for M2 macrophage activation in patients with enthesitis-related arthritis category of juvenile idiopathic arthritis.

Authors:  Shruti Bhattacharya; Akhilesh Yadav; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2019-02-08       Impact factor: 2.980

Review 5.  Biomarkers in spondyloarthritis.

Authors:  Kyoung-Sun Na; Tae-Hwan Kim; Robert D Inman
Journal:  Curr Rheumatol Rep       Date:  2006-08       Impact factor: 4.592

6.  The role of tumor necrosis factor-like weak inducer of apoptosis in atherosclerosis via its two different receptors.

Authors:  Hengdao Liu; Dan Lin; Hong Xiang; Wei Chen; Shaoli Zhao; Hui Peng; Jie Yang; Pan Chen; Shuhua Chen; Hongwei Lu
Journal:  Exp Ther Med       Date:  2017-06-14       Impact factor: 2.447

7.  Serum levels of soluble CD163 in patients with systemic sclerosis.

Authors:  Wakana Nakayama; Masatoshi Jinnin; Katsunari Makino; Ikko Kajihara; Takamitsu Makino; Satoshi Fukushima; Yuji Inoue; Hironobu Ihn
Journal:  Rheumatol Int       Date:  2010-12-01       Impact factor: 2.631

8.  Expression of CD163 prevents apoptosis through the production of granulocyte colony-stimulating factor in meningioma.

Authors:  Hiromi Kanno; Hiroshi Nishihara; Lei Wang; Sayaka Yuzawa; Hiroyuki Kobayashi; Masumi Tsuda; Taichi Kimura; Mishie Tanino; Shunsuke Terasaka; Shinya Tanaka
Journal:  Neuro Oncol       Date:  2013-03-28       Impact factor: 12.300

Review 9.  CD163 and inflammation: biological, diagnostic, and therapeutic aspects.

Authors:  Anders Etzerodt; Søren K Moestrup
Journal:  Antioxid Redox Signal       Date:  2012-10-19       Impact factor: 8.401

Review 10.  Progress in spondylarthritis. Immunopathogenesis of spondyloarthritis: which cells drive disease?

Authors:  Lode Melis; Dirk Elewaut
Journal:  Arthritis Res Ther       Date:  2009-06-25       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.